84,322 Shares in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Acquired by Walleye Capital LLC

Walleye Capital LLC bought a new position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 84,322 shares of the company's stock, valued at approximately $912,000. Walleye Capital LLC owned 0.16% of 4D Molecular Therapeutics at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of FDMT. Assenagon Asset Management S.A. grew its holdings in shares of 4D Molecular Therapeutics by 238.3% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,543,414 shares of the company's stock worth $16,684,000 after purchasing an additional 1,087,147 shares during the period. Panagora Asset Management Inc. increased its position in shares of 4D Molecular Therapeutics by 247.7% during the second quarter. Panagora Asset Management Inc. now owns 354,857 shares of the company's stock valued at $7,448,000 after acquiring an additional 252,789 shares during the last quarter. Novo Holdings A S increased its position in shares of 4D Molecular Therapeutics by 7.1% during the third quarter. Novo Holdings A S now owns 1,500,000 shares of the company's stock valued at $16,215,000 after acquiring an additional 100,000 shares during the last quarter. Squarepoint Ops LLC raised its stake in shares of 4D Molecular Therapeutics by 652.7% in the 2nd quarter. Squarepoint Ops LLC now owns 110,041 shares of the company's stock valued at $2,310,000 after acquiring an additional 95,422 shares during the period. Finally, Nisa Investment Advisors LLC lifted its holdings in shares of 4D Molecular Therapeutics by 5,735.7% in the 2nd quarter. Nisa Investment Advisors LLC now owns 96,698 shares of the company's stock worth $2,030,000 after acquiring an additional 95,041 shares during the last quarter. 99.27% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have issued reports on FDMT. Royal Bank of Canada cut their target price on 4D Molecular Therapeutics from $40.00 to $39.00 and set an "outperform" rating on the stock in a research report on Thursday, November 14th. Leerink Partners reissued an "outperform" rating and set a $36.00 target price (down previously from $40.00) on shares of 4D Molecular Therapeutics in a research note on Thursday, September 19th. Chardan Capital restated a "buy" rating and set a $39.00 target price on shares of 4D Molecular Therapeutics in a report on Thursday, November 14th. HC Wainwright reiterated a "buy" rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Thursday, November 14th. Finally, Morgan Stanley started coverage on shares of 4D Molecular Therapeutics in a report on Thursday, November 21st. They issued an "underweight" rating and a $8.00 price objective for the company. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $42.13.

4D Molecular Therapeutics Stock Performance

Shares of NASDAQ:FDMT traded up $0.53 during trading hours on Friday, reaching $7.35. The stock had a trading volume of 373,867 shares, compared to its average volume of 873,860. 4D Molecular Therapeutics, Inc. has a 1 year low of $6.77 and a 1 year high of $36.25. The firm's 50 day moving average is $8.43 and its 200-day moving average is $15.25. The stock has a market capitalization of $339.79 million, a price-to-earnings ratio of -2.58 and a beta of 2.74.

4D Molecular Therapeutics Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.